Jorge E. Cortes, MD

Articles

Asciminib Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase in the Pivotal Phase 3 ASC4FIRST Study: Week 96 Update

May 15th 2025

Dr. Jorge E. Cortes presents updated week 96 results from the Phase 3 ASC4FIRST study, showing that asciminib continues to demonstrate superior efficacy and a more favorable safety profile compared with investigator-selected TKIs in newly diagnosed chronic-phase CML, reinforcing its potential as a standard of care.

Future Directions in the Management of Acute Myeloid Leukemia

March 21st 2023

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.

Emerging Treatment Strategies in Acute Myeloid Leukemia

March 21st 2023

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.

Sequencing Therapies in Patients With Relapsed/Refractory AML

March 14th 2023

Shared insight on how treatments can be optimally sequenced in patients with relapsed/refractory acute myeloid leukemia.

A Potential Role for IDH-1 Inhibitor Olutasidenib in Relapsed/Refractory AML?

March 14th 2023

Expert perspectives on the potential role of IDH1-targeted therapy, olutasidenib, in patients with relapsed/refractory acute myeloid leukemia.

Treatment Strategies in Patients With Relapsed/Refractory AML

March 7th 2023

Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.

Role of Stem Cell Transplant in Acute Myeloid Leukemia

March 7th 2023

Before closing out their discussion on first-line treatment options for patients with AML, expert oncologists reflect on the role of stem cell transplant in AML.

Novel Venetoclax-Based Regimens in Patients With AML Unfit for Intensive Chemotherapy

February 28th 2023

A comprehensive review of novel venetoclax-based combination therapy in patients unfit for intensive chemotherapy who are diagnosed with AML.

Frontline Treatment in Patients With IDH-Mutated AML Unfit for Intensive Chemotherapy

February 28th 2023

In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.

Acute Myeloid Leukemia: VEN + AZA Treatment in Patients Unfit for Intensive Chemotherapy

February 21st 2023

A brief overview of mainstay treatment options in the first-line setting of AML for patients deemed unfit for intensive chemotherapy.

Optimizing Management of TP53-Mutated Acute Myeloid Leukemia

February 21st 2023

Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.

Acute Myeloid Leukemia: Frontline Treatment With CPX-351

February 14th 2023

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Frontline Treatment Options for Patients With IDH2-Mutated AML

February 14th 2023

Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.

Frontline Therapy for Patients With AML and FLT3 Alterations

February 7th 2023

Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.

Role of Intensive Chemotherapy in Young, Fit Patients With AML

February 7th 2023

Centering focus on first-line treatment modalities, panelists highlight the ongoing role of intensive chemotherapy in the management of AML.

Acute Myeloid Leukemia: Optimizing Risk Stratification

January 31st 2023

Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.

Molecular Biomarker Testing in Acute Myeloid Leukemia

January 31st 2023

In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.

Current Classifications of Acute Myeloid Leukemia

January 24th 2023

Expert perspectives on current classification strategies in acute myeloid leukemia and how these guidelines make use of molecular markers.

Overview of Acute Myeloid Leukemia

January 24th 2023

Opening their discussion on the management of acute myeloid leukemia (AML), expert oncologists provide an overview on the incidence, diagnosis, and stratification of patients.

Dr. Cortes on Future Research Directions With CPX-351 in AML

February 26th 2021

Jorge E. Cortes, MD, discusses future directions in the research of CPX-351 in patients with acute myeloid leukemia.